← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
Sonoco's Eviosys acquisition drove a 42% revenue surge and much higher profit, but free cash flow fell and discontinued operations complicated the apparent operating leverage.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 41.7%OK
- Profitability — Net income grew 511.8% to $1.003B from $163.949MOK
- Cash flow — Free cash flow declined 21.5% to $345.759M from $440.61MWatch
- Margins — Operating margin expanded 738 bps to 13.54%OK
- Accounting — Acquisition-driven scale with weaker cash conversionNote
- Insiders — 4 purchases and 2 salesOK
Business
Sonoco manufactures metal, paper, plastic and flexible packaging for consumer and industrial products.
Where the revenue comes from
Fiscal 2025, as SONOCO PRODUCTS CO reports it. History and quarterly detail are in the app.
- Consumer Packaging$4.9B
- Industrial Paper Packaging$2.3B
Leadership changes
From SONOCO PRODUCTS CO's own filings, the day they're filed.
- Paul Joachimczyk · Chief Financial Officer · appointmenteff. 2025-06-30
- Jerry A. Cheatham · President · appointmenteff. 2025-01-03
- Paul Joachimczyk · Chief Financial Officer · appointment
Latest filings
- 8-K · Company announcement2026-08-05
- 10-Q · Quarterly report2026-07-28
- 8-K · Company announcement2026-07-22
- 8-K · Company announcement2026-05-11
- 10-Q · Quarterly report2026-04-28
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about SONOCO PRODUCTS CO, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.